CA2604884A1 - Ddr2 in cancer diagnosis, detection and treatment - Google Patents

Ddr2 in cancer diagnosis, detection and treatment Download PDF

Info

Publication number
CA2604884A1
CA2604884A1 CA002604884A CA2604884A CA2604884A1 CA 2604884 A1 CA2604884 A1 CA 2604884A1 CA 002604884 A CA002604884 A CA 002604884A CA 2604884 A CA2604884 A CA 2604884A CA 2604884 A1 CA2604884 A1 CA 2604884A1
Authority
CA
Canada
Prior art keywords
cancer
antibody
cell
ddr2
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002604884A
Other languages
English (en)
French (fr)
Inventor
Abdallah Fanidi
Robert Booher
Christin Tse
Xie Xu
Guoying Yu
Edward Moler
Michael Rowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Sagres Discovery Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2604884A1 publication Critical patent/CA2604884A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002604884A 2005-04-07 2006-04-07 Ddr2 in cancer diagnosis, detection and treatment Abandoned CA2604884A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66986005P 2005-04-07 2005-04-07
US60/669,860 2005-04-07
PCT/US2006/013162 WO2006110587A2 (en) 2005-04-07 2006-04-07 Ddr2 in cancer diagnosis, detection and treatment

Publications (1)

Publication Number Publication Date
CA2604884A1 true CA2604884A1 (en) 2006-10-19

Family

ID=37023020

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002604884A Abandoned CA2604884A1 (en) 2005-04-07 2006-04-07 Ddr2 in cancer diagnosis, detection and treatment

Country Status (6)

Country Link
US (1) US20100068207A1 (enExample)
EP (1) EP1899482A2 (enExample)
JP (1) JP4942219B2 (enExample)
AU (1) AU2006235264A1 (enExample)
CA (1) CA2604884A1 (enExample)
WO (1) WO2006110587A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652472B2 (en) 2006-12-05 2014-02-18 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9499856B2 (en) 2012-04-02 2016-11-22 The Board Institute, Inc. DDR2 mutations in squamous cell lung cancer
WO2013151677A1 (en) * 2012-04-02 2013-10-10 Broad Institute, Inc. Ddr2 mutations in cancer
CN107236816A (zh) * 2012-12-27 2017-10-10 奎斯特诊断投资股份有限公司 Ddr2突变作为黑素瘤或基底细胞癌的可靶向的特征
KR101462329B1 (ko) 2013-01-30 2014-11-21 중앙대학교 산학협력단 디스코이딘 도메인 리셉터 2의 ｊｍ2 도메인의 발현 촉진제를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
JPWO2015099197A1 (ja) * 2013-12-25 2017-03-23 国立大学法人佐賀大学 肺癌の検査方法
WO2024027770A1 (zh) * 2022-08-03 2024-02-08 菲柏生物医学技术（广州）有限公司 抗ddr2纳米抗体及其应用
CN116027038A (zh) * 2022-09-16 2023-04-28 菲创生物医学技术(广州)有限公司 盘状结构域受体2在诊断胶质瘤中的应用及相关的计算机可读介质
CN116626294B (zh) * 2022-09-20 2024-07-09 菲创生物医学技术(广州)有限公司 盘状结构域受体2在诊断神经退行性疾病中的应用及相关的计算机可读介质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
JP2004002210A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004074506A2 (en) * 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
US7659062B2 (en) * 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
BRPI0412110A (pt) * 2003-07-02 2006-11-21 Novartis Ag genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
DE602004025812D1 (de) * 2003-07-11 2010-04-15 Robert Zeillinger N mammakarzinom
WO2005007830A2 (en) * 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
WO2005015236A2 (en) * 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma

Also Published As

Publication number Publication date
WO2006110587A3 (en) 2007-03-08
AU2006235264A1 (en) 2006-10-19
US20100068207A1 (en) 2010-03-18
JP2008535855A (ja) 2008-09-04
JP4942219B2 (ja) 2012-05-30
EP1899482A2 (en) 2008-03-19
WO2006110587A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
US20070237770A1 (en) Novel compositions and methods in cancer
EP2083088A2 (en) Cancer-related genes
US20090214536A1 (en) CACNA1E in Cancer Diagnosis, Detection and Treatment
EP2196474A2 (en) Therapeutic targets in cancer
US20070274990A1 (en) Novel Therapeutic Targets in Cancer
US20080039413A1 (en) Novel compositions and methods in cancer
US7919246B2 (en) SEMA4D in cancer diagnosis, detection and treatment
US20070161003A1 (en) Novel therapeutic targets in cancer
US20070098728A1 (en) Novel compositions and methods in cancer
JP4942219B2 (ja) 癌の診断、検出および処置におけるｄｄｒ２
US20090297507A1 (en) ADAM10 in Cancer Diagnosis, Detection and Treatment
US20070042385A1 (en) Novel compositions and methods in cancer
EP2204376A2 (en) Novel therapeutic targets in cancer
US20090317391A1 (en) Cancer Related Genes (PTPE)
US20070281896A1 (en) Novel compositions and methods in cancer
CA2572509A1 (en) Novel compositions and methods in cancer

Legal Events

Date Code Title Description
FZDE Discontinued